In intention-to-treat analysis , no reduction in the risk of CVD or secondary CVD outcomes was seen for the DHA+EPA ( primary outcome : hazard ratio [ HR ] , 0.95 ; 95 % CI , 0.78-1 .17 ) or lutein + zeaxanthin ( primary outcome : HR , 0.94 ; 95 % CI , 0.77-1 .15 ) groups .